Experimental CAR-T injection aims to tame autoimmune diseases

NCT ID NCT07613411

Not yet recruiting Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants receive a single IV infusion and are monitored for side effects and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KSVCBD injection (a type of CAR-T cell therapy given by IV infusion)
What this could lead to: If successful, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to other therapies.
What could go wrong: This is a very early, small trial (60 people) focused on safety, so it's too soon to know if it works. There are risks like severe immune reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome autoimmune disease granulomatosis with polyangiitis idiopathic inflammatory myopathy immunoglobulin G4-related sclerosing disease pemphigus Sjogren syndrome systemic lupus erythematosus systemic sclerosis thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES

Contacts and locations

Locations

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.